Mo-99 Supply Chain Update from SNMMI
Much like you, the SNMMI leadership has been closely following the rapidly evolving COVID-19 situation—monitoring the latest recommendations provided by the U.S. Centers
for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to help address its inevitable impact on the nuclear
medicine and molecular imaging community. In line with the SNMMI’s mission to improve human health by advancing nuclear medicine, molecular imaging, and radionuclide therapy; SNMMI’s primary focus is on how this issue may affect
our ability to care for patients; more specifically, how the COVID-19 pandemic may affect the Mo-99 supply situation.
The SNMMI is particularly paying close attention to how the COVID-19 pandemic might affect different parts of the Mo-99 supply chain including production, target processing, and transportation. As you may
imagine, many factors can affect this supply chain, including quarantines and closures of schools that result in the absence of key staff, as well as disruptions in the international transportation network. In order to keep our
members as informed as possible, SNMMI is currently taking the following steps:
- Monitoring official government sites to obtain the most up-to-date information about the status of Mo-99 production and processing facilities;
- Reaching out to our industry partners and working with trade organizations to ensure that we provide you with the most up-to-date and accurate information Mo-99 availability; and
- Updating our membership as soon as we learn of any interruptions to the Mo-99 supply chain.
At this time, no Mo-99 shortages have been reported. Moving forward, SNMMI will remain in close contact with government agencies, trade organizations, and other stakeholders in the nuclear medicine and molecular imaging community
to help to ensure an adequate supply of Mo-99.